Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: Clinical and experimental studies

Journal of Clinical Pharmacology

Volumn 43, Issue 10, 2003, Pages 1124-1135

  Rudek, Michelle A ^a,b   Venitz, Jürgen ^b   Ando, Yuichi ^a   Reed, Eddie ^a   Pluda, James M ^a   Figg, William D ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

COL 3; Metabolism; Metastatic cancer; Pharmacokinetics

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; 4 DEDIMETHYLAMINOSANCYCLINE GLUCURONIDE; ALBUMIN; DRUG METABOLITE; GELATIN; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING KINETICS; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSOLUTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SULFATION; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; METASTASIS; PHYSICAL CHEMISTRY; PROSTATE CARCINOMA; REFRACTORY METASTATIC CANCER; STEADY STATE; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; AGED; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCURONIDES; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM METASTASIS; OROSOMUCOID; PHARMACOKINETICS; PROTEIN BINDING; SERUM ALBUMIN; TETRACYCLINES; TIME FACTORS; TREATMENT FAILURE;

EID: 0141765810     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003256675     Document Type: Article

References (46)

1. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-193.
2. Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, et al: Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001;19:584-592.
3. Pinsuwan S, Alvarez-Nunez FA, Tabibi ES, Yalkowsky SH: Degradation kinetics of 4-dedimethylamino sancycline, a new anti-tumor agent, in aqueous solutions. Int J Pharm 1999;181:31-40.
4. Li J, Huynh H, Chan E: Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration. Pharm Res 2002;19:1655-1662.
5. Nelis HJ, De Leenheer AP: Metabolism of minocycline in humans. Drug Metab Dispos 1982;10:142-146.
6. Bocker R: Analysis and quantitation of a metabolite of doxycycline in mice, rats, and humans by high-performance liquid chromatography. J Chromatogr 1983;274:255-262.
7. Schach von Wittenau M, Twomey TM: The disposition of doxycyline by man and dog. Chemotherapy 1971;16:217-228.
8. Schach von Wittenau M: Some pharmacokinetic aspects of doxycycline metabolism in man. Chemotherapy 1968;13(Suppl.):50.
9. Neuvonen PJ, Penttila O, Lehtovaara R, Aho K: Effect of antiepileptic drugs on the elimination of various tetracycline derivatives. Eur J Clin Pharmacol 1975;9:147-154.
10. Newman EC, Frank CW: Circular dichroism spectra of tetracycline complexes with Mg+2 and Ca+2. J Pharm Sci 1976;65:1728-1732.
11. Rudek MA, March CL, Bauer KS Jr, Pluda JM, Figg WD: High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. J Pharm Biomed Anal 2000;22:1003-1014.
12. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979;9:115-134.
13. DuBois D, DuBois EF: A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-871.
14. Morgan DJ, Bray KM: Lean body mass as a predictor of drug dosage: implications for drug therapy. Clin Pharmacokinet 1994;26:292-307.
15. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, et al: The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999;93:4436-4440.
16. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. Gibaldi M, Perrier D: Pharmacokinetics: Drugs and the Pharmaceutical Sciences. 2nd ed. New York: Marcel Dekker, 1982.
18. Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, et al: The P-glycoprotein antagonist psc 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 2001;7:1610-1617.
19. Walle T, Walle UK: Stereoselective sulfate conjugation of racemic 4-hydroxypropranolol by human and rat liver cytosol. Drug Metab Dispos 1991;19:448-453.
20. Rein G, Glover V, Sandler M: Multiple forms of phenolsulphotransferase in human tissues: selective inhibition by dichloronitrophenol. Biochem Pharmacol 1982;31:1893-1897.
21. Green MD, Bishop WP, Tephly TR: Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 1995;23:299-302.
22. Pinsuwan S, Alvarez-Nunez FA, Tabibi SE, Yalkowsky SH: Spectrophotometric determination of acidity constants of 4-dedimethylamino sancycline (Col-3), a new antitumor drug. J Pharm Sci 1999;88:535-537.
23. Jackson PR, Tucker GT, Woods HF: Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther 1982;32:295-302.
24. Zini R, Riant P, Barre J, Tillement JP: Disease-induced variations in plasma protein levels: implications for drug dosage regimens (part I). Clin Pharmacokinet 1990;19:147-159.
25. Rossing N: Albumin metabolism in neoplastic diseases. Scand J Clin Lab Invest 1968;22:211-216.
26. Benet LZ, Hoener BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-121.
27. Cheng Z, Rios GR, King CD, Coffman BL, Green MD, Mojarrabi B, et al: Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, 4, and 2B7. Toxicol Sci 1998;45:52-57.
28. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 1998;26:507-512.
29. Ciotti M, Lakshmi VM, Basu N, Davis BB, Owens IS, Zenser TV: Glucuronidation of benzidine and its metabolites by cDNA-expressed human UDP-glucuronosyltransferases and pH stability of glucuronides. Carcinogenesis 1999;20:1963-1969.
30. Gall WE, Zawada G, Mojarrabi B, Tephly TR, Green MD, Coffman BL, et al: Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. J Steroid Biochem Mol Biol 1999;70:101-108.
31. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, et al: 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497-502.
32. Breyer-Pfaff U, Mey U, Green MD, Tephly TR: Comparative N-glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos 2000;28:869-872.
33. Sabolovic N, Magdalou J, Netter P, Abid A: Nonsteroidal anti-inflammatory drugs and phenols glucuronidation in Caco-2 cells: identification of the UDP-glucuronosyltransferases UGT1A6, 1A3, and 2B7. Life Sci 2000;67:185-196.
34. Hagenauer B, Salamon A, Thalhammer T, Kunert O, Haslinger E, Klingler P, et al: In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos 2001;29:407-414.
35. King CD, Rios GR, Green MD, Tephly TR: UDP-glucuronosyltransferases. Curr Drug Metab 2000;1:143-161.
36. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA: The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 2001;33:273-297.
37. Fisher MB, Vandenbranden M, Findlay K, Burchell B, Thummel KE, Hall SD, et al: Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 2000;10:727-739.
38. Mackenzie PI, Miners JO, McKinnon RA: Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000;38:889-892.
39. Campistron G, Coulais Y, Caillard C, Mosser J, Pontagnier H, Houin G: Pharmacokinetics and bioavailability of doxycycline in humans. Arzneimittelforschung 1986;36:1705-1707.
40. Doluisio JT, Dittert LW: Influence of repetitive dosing of tetracyclines on biologic half-life in serum. Clin Pharmacol Ther 1969;10:690-701.
41. Raghuram TC, Krishnaswamy K: Pharmacokinetics and plasma steady state levels of doxycycline in undernutrition. Br J Clin Pharmacol 1982;14:785-789.
42. Rosenblatt JE, Barrett JE, Brodie JL, Kirby WM: Comparison of in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. Antimicrob Agents Chemother 1966;6:134-141.
43. Powis G: A study of the interaction of tetracycline with human serum lipoproteins and albumin. J Pharm Pharmacol 1974;26:113-118.
44. Wojcicki J, Kalinowski W, Gawronska-Szklarz B: Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia. Arzneimittelforschung 1985;35:991-993.
45. Kunin CM: Comparative serum binding, distribution and excretion of tetracycline and a new analogue, methacycline. Proc Soc Exper Biol Med 1962;110:311-315.
46. Cianfrocca M, Cooley TP, Lee M, Rudek MA, Scadden DT, Ratner L, et al: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002;20:153-159.